Preempt future health risks.
Cited over 20,000 times in 2021 as a pioneer in predictive intelligence.
Analysis & Insights
AstraZeneca’s infant RSV drug Beyfortus could generate $1.1bn sales revenue
Airfinity analysis shows Astrazeneca's monoclonal infant RSV drug could be administered to up to 3.5 million infants under one year of age in Europe once approved which would generate a potential revenue of up to $1.1bn.
Read More →More from Airfinity
18 million monkeypox vaccines needed to protect most at risk, 85 million to protect wider gay community and health workersAstraZeneca and Pfizer/BioNTech saved over 12 million lives in the first year of vaccinationSales of COVID-19 antiviral pill Paxlovid to leap frog Merck’s competitor MolnupiravirGlobal wastage of COVID-19 vaccines could be 1.1 billion dosesAirfinity appoints its first ever Chief Product Officer, Colin WilliansKey factors hindering global oral antiviral uptakeView All →In the News
China Is Stuck With Its Zero-Covid Policy Because of Weak VaccinesBarron's | Sep 13, 2022
Omicron boosters are a key milestone, but aren’t likely to woo new investors to Pfizer, ModernaCNBC | Sep 7, 2022
How nasal-spray vaccines could change the pandemicNature | Sep 6, 2022
Airfinity estimates a shortage of up to 55 million monkeypox vaccine dosesCinco Días | Aug 29, 2022
View All →
A pioneer in predictive health intelligence
Understand
What's happening in a given disease area?
Airfinity is the most comprehensive, single source of intelligence for new developments in your chosen area.
Predict
Identify the true need for a vaccine or a treatment.
Our suite of dynamic predictive indicators help you navigate highly dynamic and uncertain market developments and see the real opportunities.
Act
Maximise impact to save lives
Our analytics and probabilistic tools inform key decisions on resource allocation, investment and procurement decisions to maximise impact of a given drug or vaccine and ultimately improve as many lives as possible.
The world's most comprehensive infectious disease solutions.
Airfinity combines proprietary surveillance tools and forecast models with expert analysis for dozens of infectious diseases, including COVID-19, Monkeypox, Influenza and RSV.
OUR PLATFORM:
New science
Market & Production
Policies
Disease & Prevalence
What our users say?
“The Airfinity report is a guide for world leaders to fix a more ambitious action plan.”
Gordon Brown, WHO Ambassador for Global Health Financing & former UK Prime Minister
“Airfinity has been instrumental in our country's COVID response.”
Head of UK Government
Vaccine Task Force
“Vaccine production data from Airfinity has been spot on. In a fast moving pandemic, these forecasts are really important for evidence-based policy making.”
Director General,
IFPMA
“Airfinity has been critical in furnishing us and the rest of the world with COVID-19 numbers.”
James Fransham, Data Journalist,
The Economist